切换至 "中华医学电子期刊资源库"

中华眼科医学杂志(电子版) ›› 2025, Vol. 15 ›› Issue (02) : 119 -123. doi: 10.3877/cma.j.issn.2095-2007.2025.02.010

综述

中心性浆液性脉络膜视网膜病变的研究进展
王劲博1, 张朝霞2, 孙斌2,   
  1. 1. 030001 太原,山西医科大学第一临床医学院2022级硕士研究生
    2. 030002 太原,眼科学山西省重点实验室 山西省眼科医院眼眶科
  • 收稿日期:2025-01-18 出版日期:2025-04-28
  • 通信作者: 孙斌
  • 基金资助:
    山西省自然科学基金项目(20210302123344)

Advance on the central serous chorioretinopathy

Jinbo Wang1, Zhaoxia Zhang2, Bin Sun2,   

  1. 1. Master′s degree 2022,the First Clinical Medical College of Shanxi Medical University,Taiyuan 030001,China
    2. Department of Orbital Ophthalmology,Shanxi Province Key Laboratory of Ophthalmology,Shanxi Eye Hospital,Taiyuan 030002,China
  • Received:2025-01-18 Published:2025-04-28
  • Corresponding author: Bin Sun
引用本文:

王劲博, 张朝霞, 孙斌. 中心性浆液性脉络膜视网膜病变的研究进展[J/OL]. 中华眼科医学杂志(电子版), 2025, 15(02): 119-123.

Jinbo Wang, Zhaoxia Zhang, Bin Sun. Advance on the central serous chorioretinopathy[J/OL]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2025, 15(02): 119-123.

中心性浆液性脉络膜视网膜病变(CSC)是以视网膜神经上皮层局限性且浆液性脱离为特征的疾病,常累及黄斑区,伴有视网膜色素上皮(rPE)功能障碍、视网膜色素上皮层脱离(PED)、脉络膜增厚、高渗透性及静脉瘀滞等。CSC的发病机制虽尚未明确,但脉络膜病变及RPE功能障碍却贯穿CSC发病的整个病理变化过程,临床治疗重点为复位脱离的视网膜,但脉络膜病变仍是CSC治疗的难点。本文中笔者就CSC脉络膜病变的研究进展进行综述。

Central serous chorioretinopathy(CSC)is characterized by localized,serous retinal detachment,most affect at the macular,usually associated with pigment epithelial detachments(PED),retinal pigment epithelial(rPE)dysfunction,and choroidal thickening,hyperpermeability and venous overload.The etiological mechanism and pathogenesis of CSC are not yet completely understood,but choroidal lesions and RPEdysfunction are integral to its entire pathological progression.The treatment always focuses on resolving the retinal detachment,but choroid lesions in CSC are still in difficulties.The progress of choroid disease in CSC was reviewed in this paper.

图1 中心性浆液性脉络膜视网膜病变患者治疗前后的影像学成像 患者,男性,38岁,左眼视物变小3个月余;图A示患者治疗前荧光素眼底血管造影成像,可见荧光渗漏部位(见红色圆圈);图B示患者治疗前光学相干断层扫描成像,可见视网膜色素上皮病变部位脉络膜厚度为493μm;图C示患者治疗前光学相干断层扫描成像,可见视网膜色素上皮病变部位黄斑中心凹下脉络膜厚度为457μm;图D示患者阈下微脉冲激光治疗一个月后光学相干断层扫描成像,可见视网膜色素上皮病变部位脉络膜厚度为359μm;图E示患者阈下微脉冲激光治疗一个月后光学相干断层扫描成像,可见视网膜色素上皮病变部位黄斑中心凹下脉络膜厚度为366μm;图F示患者阈下微脉冲激光治疗一个月后光学相干断层扫描成像,可见视网膜色素上皮病变部位脉络膜厚度为387μm;图G示患者阈下微脉冲激光治疗一个月后光学相干断层扫描成像,可见视网膜色素上皮病变部位黄斑中心凹下脉络膜厚度为391μm
[1]
Çiloĝlu E,Unal F,Dogan NC.The relationship between the central serous chorioretinopathy,choroidal thickness,and serum hormone levels[J].Graefes Arch Clin Exp Ophthalmol,2018,256(6):1111-1116.
[2]
Fung AT,Yang Y,Kam AW.Central serous chorioretinopathy:A review[J].Clin Exp Ophthalmol,2023,51(3):243-270.
[3]
Tsai DC,Chen SJ,Huang CC,et al.Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: a population-based study[J].PloSOne,2013,8(6):1-7.
[4]
Mehta PH,Chhablani J, Wang J, et al. Central serous chorioretinopathy in African Americans at Wilmer eye institute[J].J Natl Med Assoc,2018,110(3):297-302.
[5]
Pan CK,Vail D,Bhattacharya J,et al.The effect of obstructive sleep apnea on absolute risk of central serous chorioretinopathy[J].Am JOphthalmol,2020,218:148-155.
[6]
李建军,张风.中心性浆液性脉络膜视网膜病变的治疗进展[J].眼科,2011,20(6):230-234.
[7]
Chhablani J,Cohen FB.Multimodal imaging-based central serous chorioretinopathy classification[J].Ophthalmol Retina,2020,4(11):1043-1046.
[8]
徐丽,王治骞,庄晓彤.中心性浆液性脉络膜视网膜病变研究近况及治疗[J].中国实用眼科杂志,2017,35(6):553-557.
[9]
Irini C. Risk factors for central serous chorioretinopathy:Multivariate approach in a case-control study[J].Curr Eye Res,2017,42(7):1069-1073.
[10]
Youngsub E.Systemic factors associated with central serous chorioretinopathy in Koreans[J].Korean J Ophthalmol,2012,26(4):260-264.
[11]
Singh SR,Dogra M,Dogra MR,et al.Dark spot in fibrinous central serous chorioretinopathy[J].JAMA Ophthalmol,2018,21(3):201-206.
[12]
Rijssen TJV,Dijk EHCV,Yzer S, et al. Central serous chorioretinopathy:Towards an evidence-based treatment guideline[J].Prog Retin Eye Res,2019,73:100770.
[13]
Hanumunthadu D,Tan ACS,Singh SR,et al.Management of chronic central serous chorioretinopathy[J]. Indian J Ophthalmol,2017,66(12):1704-1714.
[14]
Sugiura A,Fujino R,Takemiya N,et al.The association between visual function and retinal structure in chronic central serous chorioretinopathy[J].Sci Rep,2017,7(1):16288.
[15]
Guyer DR,Yannuzzi LA,Slakter JS,et al.Digital indocyanine green videoangiography of central serous chorioretinopathy[J].Arch Ophthalmol,1994,112(8):1057-1062.
[16]
Piccolino FC,Borgia L.Central serous chorioretinopathy and indocyanine green angiography[J].Retina,1994,14(3):231-242.
[17]
Prünte C.Indocyanine green angiographic findings in central serous chorioretinopathy[J].Int Ophthalmol,1995,19:77-82.
[18]
Kitaya N,Nagaoka T,Hikichi T,et al.Features of abnormal choroidal circulation in central serous chorioretinopathy[J].Br J Ophthalmol,2003,87(6):709-712.
[19]
Kaye RA,Peto T,Hogg R,et al.Choroidal vascularity in chronic central serous chorioretinopathy and its association with risk single-nucleotide polymorphisms[J].Retina,2022,44(5):837-843.
[20]
Kaye R, Chandra S, Sheth J, et al. Central serous chorioretinopathy:An update on risk factors,pathophysiology and imaging modalities[J].Prog Retin Eye Res,2020,79:100865.
[21]
Lee M,Lee H,Kim HC,et al.Changes in stromal and luminal areas of the choroid in pachychoroid diseases:insights into the pathophysiology of pachychoroid diseases[J].Invest Ophthalmol Vis Sci,2018,59(12):4896-4908.
[22]
Schubert C,Pryds A,Zeng S,et al.Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy[J].Hum Mutat,2014,35(7):859-867.
[23]
Yang HS,Kang TG,Park H,et al.Quantitative evaluation of choriocapillaris using optical coherence tomography and optical coherence tomography angiography in patients with central serous chorioretinopathy after half-dose photodynamic therapy[J].PLoS One,2020,15(1):e0227718.
[24]
Maruko I,Iida T,Sugano Y,et al.Subfoveal choroidal thickness after treatment of central serous chorioretinopathy[J].Ophthalmology,2010,117(9):1792-1799.
[25]
Feenstra HM,Van-Dijk EH,Cheung CMG,et al.Central serous chorioretinopathy:An evidence-based treatment guideline[J].Prog Retin Eye Res,2024,101:101236.
[26]
He G,Zhang X,Gan Y,et al.Choroidal vein alterations in pachychoroid disease with choroidal vascular hyperpermeability:Evaluated by wide-field indocyanine green angiography[J].Invest Ophthalmol Vis Sci,2023,64(11):25.
[27]
Warrow DJ,Hoang QV,Freund KB.Pachychoroid pigment epitheliopathy[J].Retina,2013,33(8):1659-1672.
[28]
Zhang X,Sivaprasad S.Drusen and pachydrusen:the definition,pathogenesis,and clinical significance[J].Eye,2021,35(1):121-133.
[29]
Cheung CMG,Lee WK,Koizumi H,et al.Pachychoroid disease[J].Eye,2018,33(1):14-33.
[30]
Dansingani KK,Balaratnasingam C,Naysan J,et al.En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography[J].Retina,2016,36(3):499-516.
[31]
Baek J,Lee JH,Jung BJ,et al.Morphologic features of large choroidal vessel layer: age-related macular degeneration,polypoidal choroidal vasculopathy, and central serous chorioretinopathy[J].Graefes Arch Clin Exp Ophthalmol,2018,256:2309-2317.
[32]
Yamashiro K,Hosoda Y,Miyake M,et al.Characteristics of pachychoroid diseases and age-related macular degeneration:Multimodal imaging and genetic backgrounds[J].J Clin Med,2020,9(7):2034.
[33]
Moraru AD,Costin D,Moraru RL,et al.Current diagnosis and management strategies in pachychoroid spectrum of diseases(review)[J].Exp Ther Med,2020,20(4):3528-3535.
[34]
Matsumoto H,Kishi S,Mukai R,et al.Remodeling of macular vortex veins in pachychoroid neovasculopathy[J].Sci Rep,2019,9(1):14689.
[35]
沈静,谢兵.肥厚型脉络膜谱系疾病的研究进展[J].国际眼科杂志,2021,21(8):1399-1403.
[36]
Manayath GJ,Shah VS,Saravanan VR,et al.Polypoidal choroidal vasculopathy associated with central serous chorioretinopathy:Pachychoroid spectrum of diseases[J].Retina,2018,38(6):1195-1204.
[37]
李璐希,张鹏.肥厚型脉络膜疾病谱的研究进展[J].中华眼科杂志,2023,59(1):68-72.
[38]
Yang S,Zhou J,Li DW.Functions and diseases of the retinal pigment epithelium[J].Front Pharmacol,2021,12:72870.
[39]
Sagar P,Sodhi PS,Roy S,et al.Pachychoroid neovasculopathy:A comparative review on pathology,clinical features,and therapy[J].Eur JOphthalmol,2021,PMID:34325545.
[40]
Sato T,Kishi S,Watanabe G,et al.Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy[J].Retina,2007,27(5):589-594.
[41]
Borooah S,Sim PY,Phatak S,et al.Pachychoroid spectrum disease[J].Acta Ophthalmol,2021,99(6):e806-e822.
[42]
Kanda P,Gupta A,Gottlieb C,et al.Pathophysiology of central serous chorioretinopathy: A literature review with quality assessment[J].Eye,2022,36(5):941-962.
[43]
Spitznas M.Pathogenesis of central serous retinopathy:a new working hypothesis[J].Graefes Arch Clin Exp Ophthalmol,1986,224:321-324.
[44]
林慧敏,张静琳.中心性浆液性脉络膜视网膜病变的发病机制及诊疗进展[J].国际眼科纵览,2019,43(3):166-169.
[45]
Gemenetzi M, De-Salvo G, Lotery AJ. Central serous chorioretinopathy:an update on pathogenesis and treatment[J].Eye,2010,24(12):1743-1756.
[46]
Newman DK.Photodynamic therapy:current role in the treatment of chorioretinal conditions[J].Eye,2016,30(2):202-210.
[47]
Feenstra HMA,Diederen RMH,Lamme M,et al.Increasing evidence for the safety of fovea-involving half-dose photodynamic therapy for chronic central serous chorioretinopathy[J].Retina,2023,43(3):379-388.
[48]
Van-Dijk EHC,Van-Rijssen TJ,Subhi Y,et al.Photodynamic therapy for chorioretinal diseases:A practical approach[J].Ophthalmol Ther,2020,9(2):329-342.
[49]
Iĝk MU, Deĝirmenci MFK, Saĝllk A. Efficacy of the subthreshold micropulse yellow wavelength laser photostimulation in the treatment of chronic central serous chorioretinopathy[J].Int JOphthalmol,2020,13(9):1404-1410.
[50]
Mohabati D,Boon CJF,Yzer S.Risk of recurrence and transition to chronic disease in acute central serous chorioretinopathy[J].Clin Ophthalmol,2020,14:1165-1175.
[51]
Zhao MW,Zhang F,Chen YX,et al.A 50% vs 30% dose of verteporfin(photodynamic therapy)for acute central serous chorioretinopathy:One-year results of a randomized clinical trial[J].JAMA Ophthalmol,2015,133(3):333-340.
[52]
Van-Rijssen TJ,Van-Dijk EH,Dijkman G,et al.Reply to comment on:Crossover to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous chorioretinopathy[J].Am JOphthalmol,2021,222:397-398.
[53]
Bandello F, Lanzetta P, Furlan F, et al. Non visible subthreshold micropulse diode laser treatment of idiopathic central serous chorioretinopathy.A pilot study[J].Invest Ophthalmol Vis Sci,2003,44(13):4858.
[54]
赵会孟,张有花,解孝锋.微脉冲激光在眼科疾病中的应用进展[J].中国中医眼科杂志,2023,33(2):170-174.
[55]
Ambiya V,Goud A,Mathai A,et al.Microsecond yellow laser for subfoveal leaks in central serous chorioretinopathy[J].Clin Ophthalmol,2016,10:1513-1519.
[56]
Prasuhn M,Miura Y,Tura A,et al.Influence of retinal microsecond pulse laser treatment in central serous chorioretinopathy:A short-term optical coherence tomography angiography study[J].Preprints,2021,10(11):2418.
[57]
吴妍,陈放,李喆.微脉冲激光治疗慢性中心性浆液性脉络膜视网膜病变的短期效果观察[J].中华眼外伤职业眼病杂志,2022,44(12):881-888.
[58]
Arsan A,Kanar HS,Sonmez A.Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser(577-nm)treatment for chronic central serous chorioretinopathy:long-term follow-up[J].Eye,2018,32(4):726-733.
[1] 曾春琴, 沈强, 周厚利, 李双龙, 胡高铭. 糖尿病视网膜病变中视网膜色素上皮脂代谢异常的研究进展[J/OL]. 中华眼科医学杂志(电子版), 2025, 15(01): 50-54.
[2] 毕燃, 白赫南, 朱丹. 半剂量维替泊芬光动力疗法治疗复发性中心性浆液性脉络膜视网膜病变的临床观察[J/OL]. 中华眼科医学杂志(电子版), 2018, 08(03): 122-127.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?